Western drugmakers allegedly paid large bonuses to Russian distributors for cancer drug contracts
A whistleblower report submitted to U.S. regulators says Merck, Eli Lilly, Novartis and AstraZeneca gave Russian middlemen bonuses ranging from 15% to 35% to secure state contracts for cancer medicines. The payments are alleged to have funded kickbacks to officials, creating a near‑monopoly for distributors such as R‑Pharm on drugs like Keytruda. The companies either declined to comment or provided limited statements. The disclosures were published by the ICIJ, Proekt and Republik.
Why it matters
The allegations could expose the companies to U.S. Foreign Corrupt Practices Act enforcement, potentially resulting in fines or other penalties, as noted by the SEC filings referenced in the reports. Investors should watch for any regulatory actions or settlements that may affect the firms' financial results.
Key facts
- 1The whistleblower documents claim the four companies paid bonuses of between 15% and 35% to Russian distributors. icij.org
- 2Merck’s Russian distributor R‑Pharm secured $360 million in state contracts for Keytruda, winning 2,400 of nearly 5,000 bids between 2020 and 2022. themoscowtimes.com
- 3Eli Lilly allegedly budgeted a 34% bonus for its cancer drug Cyramza in 2022. themoscowtimes.com
- 4AstraZeneca’s drug Tagrisso was sold to Russian state hospitals at prices at least $3,000 per box, often above the official list price. themoscowtimes.com
- 5Novartis was reported to have identified bid‑rigging examples for its drug Kisqali in government auctions. themoscowtimes.com
- 6The SEC and the Justice Department declined to comment on the filings to ICIJ. themoscowtimes.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.